share_log

Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair

Benzinga Real-time News ·  Feb 6, 2023 04:28

Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment